Acurx Surpasses Q2 2026 EPS Estimates as Shares Slip Premarket
Acurx Pharmaceuticals posted stronger-than-expected earnings per share for the second quarter of 2026, though its stock edged lower in premarket trading.
PA
Priya Anand · Equities & Earnings Desk · 17 Aug 2026 · 1 min read
Acurx Pharmaceuticals reported its second-quarter 2026 financial results, beating consensus estimates for earnings per share.
Despite the positive earnings surprise, the company's shares slipped during premarket trading following the announcement.
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
PA
Written by
Priya Anand
Equities & Earnings Desk
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →